Applied DNA Sciences Jumps 50% Amid FDA Approves EUA Amendment

So many times Applied DNA Sciences (NASDAQ: APDN) struggled to cross $10 after the steep fall in September 2019. Entering the race of developing the COVID-19 vaccine could lift its shares near $11 but suddenly fell as other biotech companies are informing about their successes very often.

Today in APDN rose 34.56% quicky after informing FDA permits to use diagnostic kit testing capacity through the use of automated RNA extraction to treat the COVID-19 victim. Soon the demand for its shares may lift the daily volume.

Even though APDN has negative earnings short term trading investors could take a huge advantage of its rising shares. Speculation around COVID-19 may deliver a chance to soar higher.